Urso S.Parra, Carolina Cucho, V. Cubas, David Callejas, Mindy M. Cheng, S. Sanchez
{"title":"Clinical and Budget Impact of Primary HPV Genotyping for Cervical Cancer Screening in Peru","authors":"Urso S.Parra, Carolina Cucho, V. Cubas, David Callejas, Mindy M. Cheng, S. Sanchez","doi":"10.15226/2381-2915/4/1/00133","DOIUrl":null,"url":null,"abstract":"Introduction: Cervical cancer is an important public health topic in Peru as it is the second leading cause of oncology-attributed mortality among women in the country. Conventional cytology was previously the standard method for cervical cancer screening, but recognized to have low test sensitivity in detecting pre-cancerous lesions. After a growing number of countries have implemented human papillomavirus (HPV) testing as part of a primary screening approach in order to reduce the incidence of cervical cancer, Peru did the same issuing the 2017 national guidelines. The objective of this study was to compare, from the Peruvian public payer perspective, the clinical and budget impact of conventional cytology versus HPV testing with genotyping or co-testing (cytology and HPV testing with genotyping) for primary cervical cancer screening. Methods: A decision analytic model was used to estimate the clinical and budget impact of each screening approach over a ten year period. A Markov model was used to simulate the natural history (progression and regression) of HPV and project the annual incidence of cervical cancer. The analysis was conducted on a hypothetical cohort of 4,000 women between 30 and 65 years eligible for cervical cancer screening. Epidemiological and clinical data were derived from the published literature and from the Addressing THE Need for Advanced HPV Diagnostics (ATHENA) trial. The analysis included cervical cancer screening, diagnosis, and treatment costs from the national Reimbursement Tariff Listing of the Seguro Integral de Salud (SIS), Peru in addition to Peruvian gynecologic oncologists opinion when SIS costs were not available. One-way sensitivity analysis was conducted on all model inputs to evaluate the impact of uncertainty on results. Results: In the base-case analysis, 58.6%, 83.7% and 90.5% of CIN2 and CIN3 pre-cancer lesions were detected among women by conventional cytology, HPV test with genotyping and co-testing (cytology and HPV test with genotyping) respectively. Relative to conventional cytology, introduction of HPV test with genotyping is estimated to reduce the annual incidence of cervical cancer from 3.3 per 100,000 to 2.7 per 100,000 with an incremental budget impact of 0.62 USD per screened woman per year. A co-testing approach was estimated to reduce the annual incidence to 2.5 per 100,000 with budget impact of 1.37 USD per screened woman per year. Conclusions: HPV primary screening with genotyping, either implemented alone or as part of a co-testing approach, improves early cervical cancer detection and reduces cervical cancer incidence and associated mortality with minimal budget impact on a per screened woman per year basis. Including HPV primary screening with genotyping for the screening of women aged 30 to 65 years may be a cost-beneficial approach to reduce cervical cancer incidence among women in Peru. Keywords: Cervical Cancer; Budget Impact; HPV Primary Screening; Peru Abbreviations: ATHENA: Addressing THE Need for Advanced HPV Diagnostics; SIS: Seguro Integral de Salud; HPV: Human Papillomavirus; CIN: Cervical Intraepithelial Neoplasia; USD: United States Dollars; ICC: Invasive Cervical Cancer; LSIL: low-grade squamous intraepithelial lesion; HSIL: high grade squamous intraepithelial lesion; ASC-US: Atypical Squamous Cells of Undetermined Significance","PeriodicalId":419671,"journal":{"name":"SOJ Gynecology , Obstetrics & Women's Health","volume":"47 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"SOJ Gynecology , Obstetrics & Women's Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15226/2381-2915/4/1/00133","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Introduction: Cervical cancer is an important public health topic in Peru as it is the second leading cause of oncology-attributed mortality among women in the country. Conventional cytology was previously the standard method for cervical cancer screening, but recognized to have low test sensitivity in detecting pre-cancerous lesions. After a growing number of countries have implemented human papillomavirus (HPV) testing as part of a primary screening approach in order to reduce the incidence of cervical cancer, Peru did the same issuing the 2017 national guidelines. The objective of this study was to compare, from the Peruvian public payer perspective, the clinical and budget impact of conventional cytology versus HPV testing with genotyping or co-testing (cytology and HPV testing with genotyping) for primary cervical cancer screening. Methods: A decision analytic model was used to estimate the clinical and budget impact of each screening approach over a ten year period. A Markov model was used to simulate the natural history (progression and regression) of HPV and project the annual incidence of cervical cancer. The analysis was conducted on a hypothetical cohort of 4,000 women between 30 and 65 years eligible for cervical cancer screening. Epidemiological and clinical data were derived from the published literature and from the Addressing THE Need for Advanced HPV Diagnostics (ATHENA) trial. The analysis included cervical cancer screening, diagnosis, and treatment costs from the national Reimbursement Tariff Listing of the Seguro Integral de Salud (SIS), Peru in addition to Peruvian gynecologic oncologists opinion when SIS costs were not available. One-way sensitivity analysis was conducted on all model inputs to evaluate the impact of uncertainty on results. Results: In the base-case analysis, 58.6%, 83.7% and 90.5% of CIN2 and CIN3 pre-cancer lesions were detected among women by conventional cytology, HPV test with genotyping and co-testing (cytology and HPV test with genotyping) respectively. Relative to conventional cytology, introduction of HPV test with genotyping is estimated to reduce the annual incidence of cervical cancer from 3.3 per 100,000 to 2.7 per 100,000 with an incremental budget impact of 0.62 USD per screened woman per year. A co-testing approach was estimated to reduce the annual incidence to 2.5 per 100,000 with budget impact of 1.37 USD per screened woman per year. Conclusions: HPV primary screening with genotyping, either implemented alone or as part of a co-testing approach, improves early cervical cancer detection and reduces cervical cancer incidence and associated mortality with minimal budget impact on a per screened woman per year basis. Including HPV primary screening with genotyping for the screening of women aged 30 to 65 years may be a cost-beneficial approach to reduce cervical cancer incidence among women in Peru. Keywords: Cervical Cancer; Budget Impact; HPV Primary Screening; Peru Abbreviations: ATHENA: Addressing THE Need for Advanced HPV Diagnostics; SIS: Seguro Integral de Salud; HPV: Human Papillomavirus; CIN: Cervical Intraepithelial Neoplasia; USD: United States Dollars; ICC: Invasive Cervical Cancer; LSIL: low-grade squamous intraepithelial lesion; HSIL: high grade squamous intraepithelial lesion; ASC-US: Atypical Squamous Cells of Undetermined Significance
引言:在秘鲁,子宫颈癌是一个重要的公共卫生问题,因为它是该国妇女因肿瘤导致死亡的第二大原因。传统细胞学以前是宫颈癌筛查的标准方法,但在检测癌前病变方面被认为灵敏度较低。在越来越多的国家将人乳头瘤病毒(HPV)检测作为初级筛查方法的一部分以减少宫颈癌发病率之后,秘鲁也采取了同样的做法,发布了2017年国家指南。本研究的目的是从秘鲁公共付款人的角度比较常规细胞学与HPV基因分型检测或联合检测(细胞学和HPV基因分型检测)对原发性宫颈癌筛查的临床和预算影响。方法:采用决策分析模型评估十年来每种筛查方法的临床和预算影响。采用马尔可夫模型模拟HPV的自然历史(进展和回归),预测宫颈癌的年发病率。这项分析是对4000名年龄在30岁至65岁之间、有资格接受宫颈癌筛查的女性进行的假设队列。流行病学和临床数据来自已发表的文献和解决高级HPV诊断需求(ATHENA)试验。该分析包括了来自秘鲁国家医疗保险报销清单(SIS)的宫颈癌筛查、诊断和治疗费用,以及在无法获得SIS费用时秘鲁妇科肿瘤学家的意见。对所有模型输入进行单向敏感性分析,评价不确定性对结果的影响。结果:在基本病例分析中,常规细胞学检查、HPV基因分型检查和联合检测(细胞学检查和HPV基因分型检查)分别检测出58.6%、83.7%和90.5%的女性CIN2和CIN3癌前病变。与传统细胞学相比,采用HPV基因分型检测估计可将宫颈癌的年发病率从每10万人3.3例降低到每10万人2.7例,每位接受筛查的妇女每年可增加0.62美元的预算影响。据估计,联合检测方法可将年发病率降至每10万人2.5例,每位接受筛查的妇女每年的预算影响为1.37美元。结论:HPV基因分型初步筛查,无论是单独实施还是作为联合检测方法的一部分,都可以提高早期宫颈癌的发现,降低宫颈癌发病率和相关死亡率,对每年每位接受筛查的妇女的预算影响最小。将HPV初级筛查与基因分型纳入30至65岁妇女的筛查中,可能是降低秘鲁妇女宫颈癌发病率的一种具有成本效益的方法。关键词:宫颈癌;预算的影响;HPV初筛;雅典娜:解决对先进HPV诊断的需求;SIS: Seguro Integral de Salud;人乳头瘤病毒;CIN:宫颈上皮内瘤变;USD:美元;ICC:浸润性宫颈癌;LSIL:低级别鳞状上皮内病变;HSIL:高度鳞状上皮内病变;ASC-US:意义不明的非典型鳞状细胞